Heberprot-P^® is a novel and unique medicine indicated for diabetic foot ulcer treatment (DFU). This innovative product contains epithermal growth factor (EGF) as active pharmaceutical ingredient (APhI) to be applied by intra-lesional infiltration directly in the wound site. The therapy with Heberprot-P^® fills the gap of an urgent unmet medical need for the treatment of complex DFU.  There is a growing interest on the use of growing factors for treatment of DFUs. Therefore, a research program has been developed at the Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba, from the 90s to study the biological effects of repeated parentheral application of human recombinant epithermal growth factor (hr-EGF) in wounds.